Evidence map›Paper›PMID 39815092›Full record

ArticlePediatric research2025

Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).

Madison C B Paton, Manon Benders, Remy Blatch-Williams, Elizabeth Dallimore, Adam Edwards, Ngaire Elwood, Kylie Facer, Megan Finch-Edmondson, Natasha Garrity, Adrienne Gordon and 14 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Madison C B PatonCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Manon BendersWilhemina Children's Hospital, Neonatology Department, Utrecht Brain Center, University Medical Centre, University Utrecht, Utrecht, The Netherlands.
Remy Blatch-WilliamsCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Elizabeth DallimoreArgenica Therapeutics LTD, Nedlands, WA, Australia.
Adam EdwardsArgenica Therapeutics LTD, Nedlands, WA, Australia.
Ngaire ElwoodDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.
Kylie FacerParent with Lived Experience, Sydney, Australia.
Megan Finch-EdmondsonCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Natasha GarrityCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Adrienne GordonDiscipline of Obstetrics, Gynaecology, and Neonatology, The University of Sydney, Sydney, NSW, Australia.
Rod W HuntCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Graham JenkinThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Courtney A McDonaldThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, Australia.
Justin MooreDepartment of Neurosurgery, Monash Health, Melbourne, VIC, Australia.
Marcel F NoldDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.
Iona NovakCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Himanshu PopatThe Children's Hospital at Westmead, Sydney, NSW, Australia.
Carlos SalomonExosome Biology Laboratory, University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia.
Yoshiaki SatoDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, Japan.
Mary TolcosSchool of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia.
Julie A WixeyPerinatal Research Centre, University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia.
Tamara YawnoDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.
Lindsay ZhouDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia.
Atul MalhotraDepartment of Paediatrics, Monash University, Melbourne, VIC, Australia. atul.malhotra@monash.edu.ORCID http://orcid.org/0000-0001-9664-4182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapies as treatments for neonatal conditions have attracted significant research and parent interest over the last two decades. Mesenchymal stromal cells, umbilical cord blood cells and neural stem cells translate from lab, to preclinical and into clinical trials, with contributions being made from all over the world. Effective and timely translation involves frequent reflection and consultation from research-adjacent fields (i.e. cell therapies for cerebral palsy, adult neurology, companies, and regulatory bodies) as well as meaningful involvement of people with lived experience. Progress to date suggests that aligning outcome and data reporting in later phase clinical trials will support our sector, as well as involving industry partners for streamlined solutions in cell manufacturing, commercialisation and regulatory processes. Importantly, our field can also benefit from resource sharing and research collaboration in novel drug therapies, small molecules and extracellular vesicles as we attempt to bridge preclinical and clinical research. In this review, we present highlights and learnings from the second Neonatal Cell Therapies Symposium (2024), held in Sydney, Australia. IMPACT: Multiple cell therapy candidates have advanced through preclinical and clinical trials in neonatology, showing promising feasibility, safety and efficacy. Effective and timely translation is enabled by collaboration across research-adjacent fields, commercial partnerships, harmonising research outcomes and meaningful involvement of people with lived experience. Progress on the potential utility of cell therapies for neonatal conditions and further translational considerations are discussed in this paper.

Indexed as

Cell- and Tissue-Based TherapyNeonatologyAnimalsClinical Trials as TopicHumansInfant, NewbornTranslational Research, Biomedical

Identifiers

PMID39815092
PMCPMC12507666

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.